3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
4
Recruiting
2
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
71
OTHER_GOV
3
INDUSTRY
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Myeloma
1
Lung Neoplasms
1
Interventions
pembrolizumab
241
Carboplatin
170
Injections
139
Paclitaxel
122
Gemcitabine
118
Bevacizumab
117
Cisplatin
108
Pemetrexed
80
Docetaxel
80
Cyclophosphamide
74
Capecitabine
69
Fluorouracil
67
Oxaliplatin
65
Fulvestrant
60
Nivolumab
55
Cetuximab
53
fludarabine
52
Leucovorin
51
130-nm albumin-bound paclitaxel
50
Dexamethasone
46
Rituximab
41
atezolizumab
38
venetoclax
35
toripalimab
35
Drug Therapy
35
enzalutamide
32
Prednisone
32
Letrozole
32
Irinotecan
32
durvalumab
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Neoadjuvant Therapy
×
Clear all
NCT06788912
2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT07149857
2026-05-08
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2
Recruiting
60 enrolled